Lapatinib May Up Survival in High-EGFR-Expressing RCC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

The investigational agent lapatinib (Tykerb, GlaxoSmithKline) extended survival in the 61% of renal cell carcinoma (RCC) patients whose tumors overexpressed EGFR at the 3+ level

ATLANTA—The investigational agent lapatinib (Tykerb, GlaxoSmithKline) extended survival in the 61% of renal cell carcinoma (RCC) patients whose tumors overexpressed EGFR at the 3+ level, Alain Ravaud, MD, PhD, said at the American Society of Clinical Oncology 42nd Annual Meeting (abstract 4502). Lapatinib is an inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 (also known as HER2) tyrosine kinases. [See ONI June 2006, pg 1 for a report of lapatinib in metastatic HER2-positive breast cancer.] Dr. Ravaud, of University Hospital of Bordeaux, France, reported results of a randomized, open-label phase III trial comparing lapatinib with hormonal therapy in RCC patients for whom first-line cytokine treatment had failed.

"Although additional clinical trials are necessary, our findings suggest that lapatinib could be a new treatment option, along with immunological therapies and antiangiogenesis agents, for patients with advanced renal cell carcinoma that produces high levels of EGFR," Dr. Ravaud said. However, this conclusion was based on a subgroup analysis, and the trial failed to meet its primary endpoint of improved time to progression (TTP).

Patients with advanced renal cell cancer of any histology were randomized to receive oral lapatinib 1,250 mg/d or hormonal therapy (megestrol acetate or tamoxifen, which were standard treatment in 2002 when the trial was designed).

Dr. Ravaud said that at the time of the TTP analysis, 417 patients had been randomized, and 298 TTP events had been reported. At that point, neither median TTP nor median overall survival (OS) differed significantly between the lapatinib and hormone therapy groups.

Subgroup Analysis

In subgroup analysis, there was no significant effect of lapatinib in patients who overexpressed EGFR at the 2+ level (by IHC), but those who overexpressed EGFR at the 3+ level (n = 241) had significantly longer median OS (46 weeks vs 37.9 weeks, HR 0.69, P = .019) and showed a trend toward longer TTP (15.1 weeks vs 10.9 weeks, HR 0.76, P = .063). Dr. Ravaud said that additional biomarker evaluation, including FISH, is underway.

No unexpected toxicities were observed, he said. The drug-related adverse effects for lapatinib included rash (44% vs 3% with hormonal therapy) and diarrhea (40% vs 3%). Dr. Ravaud added that 10 patients receiving lapatinib had grade 3-4 diarrhea.

"The EGFR/ErbB2 dual targeted inhibitor, lapatinib, appears to prolong overall survival, compared to hormone therapy, in advanced RCC patients with overexpressed EGFR who failed prior therapy," Dr. Ravaud concluded.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content